Moderna raises full-year COVID vaccine sales forecast to $21 billion

(Reuters) – Moderna Inc (MRNA.O) on Thursday raised its full-year forecast for sales of its COVID-19 vaccine to roughly $21 billion from $19 billion.

The company in February forecast sales of $19 billion from its signed contracts, and option for $3 billion in additional purchases.

A vial and sryinge are seen in front of a displayed Moderna logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration

Moderna on Thursday forecast additional purchases of roughly $500 million.

Reporting by Manas Mishra in Bengaluru

Our Standards: The Thomson Reuters Trust Principles.

 

Reuters source:

https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-raises-full-year-covid-vaccine-sales-forecast-21-billion-2022-03-24